Roy T M, Broadstone V L, Peterson H R, Snider H L, Cyrus J, Fell R, Rothchild A H, Samols E, Pfeifer M A
Diabetic Research Unit, Louisville Veterans Administration Medical Center, KY.
Diabetes Res Clin Pract. 1990 Aug-Sep;10(1):91-7. doi: 10.1016/0168-8227(90)90086-9.
Because some aldose reductase inhibitor studies have demonstrated clinical improvement in scored neurological signs and symptoms of diabetic neuropathy, a prospective study of the effect on cardiovascular performance of sorbinil 250 mg/day for 12 months was conducted on patients with diabetic autonomic neuropathy who were free of atherosclerotic coronary artery disease and/or cardiomyopathy. After 1 year of treatment, the study group (n = 14) demonstrated significant improvement in both the resting cardiac output (P = 0.02), and the maximal cardiac output (P = 0.03). This observation suggests that the use of an aldose reductase inhibitor may be useful in treating suboptimal cardiovascular performance in patients with diabetic cardiac autonomic neuropathy.
由于一些醛糖还原酶抑制剂研究已证明糖尿病神经病变的神经学体征和症状评分有临床改善，因此对无动脉粥样硬化性冠状动脉疾病和/或心肌病的糖尿病自主神经病变患者进行了一项前瞻性研究，观察每天服用250毫克索比尼尔，持续12个月对心血管功能的影响。治疗1年后，研究组（n = 14）的静息心输出量（P = 0.02）和最大心输出量（P = 0.03）均有显著改善。这一观察结果表明，使用醛糖还原酶抑制剂可能有助于治疗糖尿病心脏自主神经病变患者的心血管功能欠佳情况。
